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Targeted Drug-Resistance Testing
Strategy for Multidrug-Resistant
Tuberculosis Detection, Lima,
Peru, 2005–2008
Gustavo E. Velásquez, Martin Yagui, J. Peter Cegielski, Luis Asencios, Jaime Bayona, Cesar Bonilla,
Hector O. Jave, Gloria Yale, Carmen Suárez, Sidney Atwood, Carmen C. Contreras, and Sonya S. Shin

The Peruvian National Tuberculosis Control Program
issued guidelines in 2006 specifying criteria for culture and
drug-susceptibility testing (DST), including district-level rapid
DST. All patients referred for culture and DST in 2 districts
of Lima, Peru, during January 2005–November 2008 were
monitored prospectively. Of 1,846 patients, 1,241 (67.2%)
had complete DST results for isoniazid and rifampin; 419
(33.8%) patients had multidrug-resistant (MDR) TB at the
time of referral. Among patients with new smear-positive
TB, household contact and suspected category I failure
were associated with MDR TB, compared with concurrent
regional surveillance data. Among previously treated
patients with smear-positive TB, adult household contact,
suspected category II failure, early relapse after category I,
and multiple previous TB treatments were associated with
MDR TB, compared with concurrent regional surveillance
data. The proportion of MDR TB detected by using guidelines
was higher than that detected by a concurrent national drugresistance survey, indicating that the strategy effectively
identified patients for DST.

M

ultidrug-resistant tuberculosis (MDR TB) is defined
as infection with Mycobacterium tuberculosis with
in vitro resistance to at least isoniazid and rifampin. The
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incidence of MDR TB disease was estimated to be 0.5
million in 2007, with a prevalence of as many as 2 million
cases worldwide (1). Although no single best approach
to MDR TB treatment has been recognized, rapid drugsusceptibility testing (DST) and prompt initiation of
effective treatment are achievable goals. Ideally, treatment
is based on timely, accurate DST, but if universal DST is
not possible or not yet available, the national TB control
program can prioritize patients at increased risk for MDR
TB.
Rapid DST methods should minimize delays to
initiation of appropriate treatment (2,3). Numerous assays
have been developed that have characteristics suitable for
use in low-income settings, including low cost, modest
technical demand, and high accuracy (4–6). The nitrate
reductase assay (NRA), also known as the Griess method,
has demonstrated acceptable sensitivity, specificity,
and speed compared with conventional DST and rapid
phenotypic DST methods (7,8). This phenotypic assay was
developed in Russia as a low-cost drug-susceptibility test
that can be used in areas of moderate technical capacity
(9). The method is based on a nitrate-reductase colorimetric
reaction that uses Lowenstein-Jensen (LJ) medium
prepared with antimicrobial drugs (9). Although initially
validated as an indirect method, it was implemented as a
direct method by the Peruvian National Institute of Health
(INS) (10). The NRA yields drug-susceptibility information
to isoniazid and rifampin 21–28 days after inoculating a
smear-positive sputum sample (direct method) or 8–10
days after obtaining a positive culture (indirect method)
(10). The pooled sensitivity and specificity of the NRA (on
culture isolates and sputum) have been reported to be 97%
and 100% for rifampin and 96% and 99% for isoniazid
(11). The pooled sensitivity and specificity of direct NRA
have been reported to be 99% and 100% for rifampin and
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94% and 100% for isoniazid (12). A recent comparison of
4 rapid DST methods with conventional DST in the context
of a clinical trial suggested they may be cost-effective when
compared with other health interventions (13). On the
basis in part of these data, the World Health Organization
(WHO) recently endorsed the use of NRA for screening
patients at risk of MDR TB (14).
Despite the development of promising commercial
and noncommercial rapid methods for MDR TB diagnosis,
how to implement those methods under program
conditions remains largely unaddressed. DST performance
in validation studies differs greatly from performance
integrated within a TB control program. Furthermore, the
performance of any method under program conditions
depends not only on assay characteristics, but also on the
assets of the laboratory network and National Tuberculosis
Control Program (NTP) guidelines which define criteria for
performing DST.
To address this gap, we evaluated the effects of a
programmatic strategy for rapid screening for MDR TB
among risk groups specified by the Peruvian NTP in April
2006 (15). At that same time, decentralized, district-level
MDR TB screening was pilot tested in 2 district laboratories
in Lima, Peru. In collaboration with the Peruvian NTP and
the Peruvian National Reference Laboratory (NRL), we
evaluated the effectiveness of these combined strategies
for detecting MDR TB. We report the proportion of drug
resistance among risk groups based on screening highrisk patients as defined by explicit criteria, including rapid
methods of DST in one of the first countries to implement
this strategy.

these services to all major provinces (4). Simultaneously,
the NTP issued national guidelines codifying criteria for
MDR TB screening on the basis of known and suspected
risk factors for MDR TB. In addition, these guidelines
recommended the use of a more aggressive empiric MDR
TB treatment regimen, including 5 second-line drugs for
those persons with suspected MDR TB pending DST
results. These programmatic and laboratory efforts resulted
in an integrated strategy to diagnose and treat MDR TB
cases in a timely and aggressive manner. During this
period, we evaluated the effectiveness of selection criteria
for DST in the first 2 laboratories (for health districts Lima
Ciudad and Lima Este) where the NRA was implemented.
For persons in whom DST to first-line drugs confirmed
drug resistance to isoniazid or rifampin, or both, the same
isolate would be sent to the NRL for testing to a full panel of
5 first-line drugs and 5 second-line drugs. DST results were
conveyed to health center providers by paper or electronic
communication, and patients were evaluated with DST
results to determine whether further regimen modification
was needed (18). Details of treatment regimens have been
described elsewhere (19). All patients diagnosed with TB
were provided directly observed therapy free of charge
through the NTP.

Materials and Methods

Enrollment Methods

Study Setting and Program Description

The prevalence of TB in Peru was 38,000 cases, and the
incidence of TB in Peru was 126 cases/100,000 population
per year, by 2007 estimates (16). The most recent national
surveillance data indicate 5.3% of new TB cases and 24%
of previously treated TB cases are MDR TB (16). In 1996,
a collaborative effort to provide individualized treatment
by using second-line drugs for MDR TB in northern Lima
was established by Partners In Health, Socios En Salud,
Harvard University, the Massachusetts State Laboratory
Institute, the Peruvian NTP, and the Peruvian INS (4). In
October 1997, the Peruvian NTP began a standardized
treatment regimen including directly observed therapy
with second-line drugs for patients in whom first-line
drugs failed (17). Only 48% of these patients were treated
successfully. During 2005 and 2006, the Peruvian INS
and NTP transferred the capacity for DST to first-line TB
drugs from the central level at the NRL to 2 district-level
reference laboratories in Lima as a prelude to decentralizing

Study Patients and Enrollment Period

The patients enrolled in this cohort had suspected TB
with respiratory symptoms living in 2 districts of Lima,
Peru, Lima Ciudad or Lima Este, who met Peruvian NTP
guidelines for DST referral as elaborated in Table 1. There
were no exclusion criteria.
Patients were identified by health care workers at their
local health care establishments, and their sputum samples
were sent to the reference laboratory for DST. Because
all sputum samples for DST were sent to the district
laboratories, subjects eligible for enrollment were identified
by this referral. Study personnel visited each district
laboratory on a regular basis to review sample referrals and
confirm that all eligible subjects had been identified. Large,
busy health centers were visited weekly and smaller, rural
health centers were visited at least monthly for review of
patient medical records. This method was used to confirm
that all patients were included who were eligible without
duplications. In Lima Ciudad, patients were enrolled from
January 2005 through March 2008. In Lima Este, patients
were enrolled from May 2005 through May 2008.
Drug Susceptibility Methods

The scale-up of MDR TB laboratory services in Peru,
including expansion of the BACTEC-460 system (Becton,
Dickinson and Company, Sparks, MD, USA) and NRA
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(Griess) method for rapid first-line DST are described
elsewhere (4,5,20). The Peruvian NRL performed
BACTEC-460 culture and DST on paucibacillary and
smear-negative samples, prioritizing pediatric cases, HIVpositive persons, and health care workers. The scale-up of
second-line conventional DST at the NRL by the indirect
agar plate proportion method has also been described
elsewhere (4). The district reference laboratories cultured
sputum specimens processed with 4% NaOH on Ogawa
medium without centrifugation. During 2005, BioSafety
Level 3 working conditions were established in 2 district
reference laboratories, and these laboratories implemented
DST on LJ medium for first-line drugs by using the indirect
proportion method. Each procedure was validated by each
laboratory through comparison with the Peruvian NRL and
the Massachusetts State Laboratory Institute. Subsequently,
the NRA was implemented in Lima Ciudad in December
2005 and in Lima Este in March 2007. The study spanned
pre- and postintervention periods: January 2005 through
November 2008 for Lima Ciudad and May 2005 through
November 2008 for Lima Este. The NRA was used for rapid
screening of smear-positive specimens from patients with
the risk factors outlined in Table 1. Sputum specimens were
processed with 2% NaOH/N-acetyl-L-cysteine, centrifuged
at 3,000 × g, cultured on LJ medium, and simultaneously
inoculated on modified LJ medium for the NRA to detect
isoniazid and rifampin resistance.
Data Collection

A team of trained data recorders prospectively collected
data using standardized forms. Sources of data included
patient charts and laboratory registries and databases. HIV
status was routinely recorded for TB patients. Available
chest radiographs were reviewed by TB physicians who
used standardized criteria to identify the type and location
of radiographic abnormalities. Chest radiograph data were
included if the radiograph was performed <1 year before
the enrollment date or <1 month after the enrollment date.
At baseline, clinical and sociodemographic data were
recorded in addition to the risk factors outlined in Table 1.
Data were entered into an Epi Info version 3.4.3 database
(Centers for Disease Control and Prevention [CDC],
Atlanta, GA, USA).
In addition to the data prospectively collected in this
study, we used national and regional data from Peruvian
NTP surveillance on drug resistance that were collected as
part of the WHO Fourth Global Report on Anti-Tuberculosis
Drug Resistance in the World (21). Surveillance and
laboratory methods are described in more detail in the
WHO report (21). For national data, we used all data in the
NTP surveillance; for regional data, we included samples
collected from health establishments served by the Lima
Ciudad and Lima Este laboratories, which corresponded to
434

the same catchment area as our study (Ministerio de Salud,
unpub. data).
Patients were identified as having MDR TB if they
had a positive culture for M. tuberculosis and DST results
showed resistance to at least isoniazid and rifampin.
Extensively drug-resistant TB was defined as resistance to
at least isoniazid, rifampin, any fluoroquinolone, and >1 of
3 injectable second-line drugs (amikacin, capreomycin, or
kanamycin). Monoresistance was defined as drug-resistance
to isoniazid or rifampin, but not both drugs. Patients were
considered to have drug-susceptible TB if their isolate
was susceptible to both isoniazid and rifampin. Baseline
refers to DST data at the time of referral, i.e., testing
performed on sputum samples collected within 30 days of
study enrollment. If baseline drug resistance data were not
available for both isoniazid and rifampin (e.g., because of a
culture-negative sample or because of contamination), the
patient was considered to have no DST result.
Statistical Analysis

All analyses were performed by using STATA/IC
version 10.1 (StataCorp LP, College Station, TX, USA).
The χ2 test or Fisher exact test was used to calculate p
values, when appropriate. Point and interval estimation
for the odds ratio were performed by using the Woolf
procedure or the exact method, when appropriate. The
Breslow-Day test for homogeneity was used to explore for
effect modification. All statistical tests were 2-sided, and
significance was set at α = 0.05.
Ethical Approval

The prospective observational cohort study providing
data for this analysis was approved by institutional review
boards at Brigham and Women’s Hospital and the Peruvian
INS. An institutional review board amendment describing
the aims of this analysis was approved by the Peruvian INS
on October 15, 2008, and by the Partners Human Research
Committee for Brigham and Women’s Hospital on
September 23, 2008. This activity was approved by CDC
as program evaluation and not as human subject research.
Results
A total of 1,846 patients were enrolled during the study
period. Among these, 605 (32.8%) did not have baseline
DST results, either due to a nonviable sample (99.2%) or
incomplete resistance data for both isoniazid and rifampin
(0.8%). The remaining 1,241 (67.2%) patients constitute
the cohort for analysis presented here.
Of these 1,241, 419 (33.8%) had baseline MDR TB,
among whom 195 (46.5%) had never been treated for TB
and 224 (53.5%) had a history of previous TB treatment.
Eight patients had extensively drug-resistant TB; 1 was
a medical student, 1 had received prior self-administered
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Table 1. Criteria for drug-susceptibility testing referral per
Peruvian National Tuberculosis Control Program guidelines*
A. Newly diagnosed smear- or culture-positive patients at risk for
MDR TB. Persons were eligible for enrollment if they were
1) diagnosed with smear-positive pulmonary TB, 2) had no
history of TB, and 3) had >1 of the following risk factors:
1. Household contact of patient with documented MDR TB
2. Household contact of patient in treatment with second-line
drugs
3. Household contact of patient who showed failure of TB
therapy
4. Household contact of patient who died of TB within the past
2 years
5. HIV-positive by ELISA and Western blot confirmation
6. Diabetes mellitus
7. Health care worker, regardless of health care field, in the
past 2 years
8. Student of health sciences in the past 2 years
9. Employee of the penitentiary system
10. Chronic treatment with corticosteroids
11. Other condition of immunosuppression
12. Adverse reaction to TB medications requiring a change in
regimen
13. Hospitalization for any indication in the past 2 years lasting
>15 days
B. Patients in whom first-line or second-line therapy may be
failing. Persons were eligible for enrollment if they were 1)
currently receiving first-line or second-line treatment, and 2) had
a sputum sample collected after >2 months of treatment that was
smear positive (i.e., monthly sputum collected between months 2
and 6)
C. Patients who had received >1 previous treatment and who did
not have documented MDR TB. This included persons who:
1. Abandoned any previous regimen and now presented for
retreatment
2. Relapsed after completion of any previous regimen within 6
months
3. Unsuccessful treatment with any previous regimen
4. Received multiple courses of TB treatment
5. Had a history of private or auto-administered treatment
D. Newly diagnosed smear-negative patients at risk for smearnegative MDR TB. Persons were eligible for enrollment if they
were 1) suspected to have active pulmonary TB, 2) were smear
negative, 3) had no history of TB therapy, and 4) had >1 of the
following risk factors:
1. Pediatric household contact of patient with documented
MDR TB
2. Pediatric household contact of patient who died of
tuberculosis within the past 2 years
3. HIV positive by ELISA and Western blot confirmation
*MDR, multidrug resistant; TB, tuberculosis.

treatment, 2 had household contacts (1 was a pediatric
patient and the other was an adult), and 4 were identified
as suspected category I failures, i.e., failure of first-line
treatment for new patients. Of these 8 case-patients, only
1 (who had received self-administered treatment) had
completed previous treatment.
Descriptive characteristics of the cohort are shown
in Table 2. Compared with patients with drug-susceptible
TB, those with MDR TB were younger, more likely to be
single, more educated, and less likely to have ever smoked.

Clinically, they were less likely to have been tested by
using the BACTEC-460 system and more likely to have
hemoptysis. MDR TB patients and patients with drugsusceptible TB did not significantly differ with respect
to their year of enrollment, gender, and history of TB
treatment. Compared with patients with drug-susceptible
TB, patients with monoresistant TB were younger and
more likely to be single.
The most frequent risk factors prompting referral for
DST among patients with new smear-positive TB were
being adults with a household contact with known or
suspected MDR TB (32.1%), diabetes mellitus (20.0%),
and suspected category I failures (19.5%). Among
previously treated patients with smear-positive TB, those
with multiple (>2) treatments (43.2%), adult household
contact (18.6%), default of category I treatment (16.8%),
and previously self-administered treatment (14.9%) were
most frequently referred for DST. Among all patients with
smear-positive TB, a single risk factor was identified in 485
(43.54%) patients, whereas 382 (34.29%), 205 (18.40%),
38 (3.41%), and 4 (0.36%) had 2, 3, 4, and 5 risk factors,
respectively (data not shown).
The prevalence of MDR TB in Peru in 2007 among
all TB patients, previously treated TB patients, and new
TB patients is shown in Table 3 (21). In this national
surveillance report, 8.3% of all TB patients, 5.2% of new
TB patients, and 24.2% of previously treated TB patients
in Peru were estimated to have MDR TB (21). Limiting
surveillance data to the 2 districts where our cohort was
enrolled, 12.4% of all TB patients, 9.9% of new TB
patients, and 24.0% of previously treated TB patients had
MDR TB (Ministerio de Salud, unpub. data). In our cohort
of 1,241 subjects, 33.8% of all patients, 31.6% of new TB
patients, and 35.8% of previously treated TB patients had
MDR TB. Because national surveillance was conducted on
smear-positive samples only, we compared the proportion
of MDR TB among patients with smear-positive results
in our cohort to prevalence of MDR TB from regional
surveillance estimates. As shown in Tables 4 and 5, our
cohort showed higher risk for MDR TB among new TB
patients and previously treated TB patients.
When stratifying our cohort by risk group, we found
that diabetes mellitus (16.8%), adult (33.5%) or child
(53.9%) patients with household contacts with known
or suspected MDR TB, and suspected category I failure,
i.e., positive smear or culture during the second or third
month of category I therapy (66.7%), were associated
with significantly higher relative risks of MDR TB among
patients with new smear-positive TB, when compared to
regional surveillance prevalence estimates. Among the 18
patients with diabetes and new smear-positive MDR TB,
10 (55.6%) had 2 risk factors for MDR TB at the time of
enrollment. Of these, 5 (27.8%) had suspected category I
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Table 2. Demographic and clinical characteristics of patients with tuberculosis, by drug-resistance status, Lima, Peru, 2005–2008*
Susceptible to INH Monoresistant to INH
Variable
and RIF, n = 661
or RIF, n = 161
MDR TB, n = 419 Total, N = 1,241
DST method
Griess
318 (48.1)
87 (54.0)
208 (49.6)
613 (49.4)
Conventional
270 (40.9)
56 (34.8)
185 (44.2)
511 (41.2)
BACTEC
63 (9.5)
17 (10.6)
23 (5.5)†
103 (8.3)
Griess/BACTEC
10 (1.5)
1 (0.6)
3 (0.7)
14 (1.1)
Year of enrollment
2005
175 (26.5)
44 (27.3)
130 (31.0)
349 (28.1)
2006
233 (35.3)
47 (29.2)
127 (30.3)
407 (32.8)
2007
178 (26.9)
48 (29.8)
106 (25.3)
332 (26.8)
2008
75 (11.4)
22 (13.7)
56 (13.4)
153 (12.3)
35.6 ± 15.2
32.8 ± 15.1†
29.7 ± 13.1‡
33.2 ± 14.8
Age, y, mean r SD
Female sex
236 (35.7)
54 (33.5)
144 (34.4)
434 (35.0)
Married or lived together
272 (41.2)
48 (29.8)§
136 (32.5)§
456 (36.7)
Unemployed, n = 1,239
257 (38.9)
62 (38.8)
155 (37.0)
474 (38.3)
Did not begin secondary level education, n = 1,235
150 (22.9)
31 (19.3)
67 (16.0)§
248 (20.1)
Tobacco use (ever), n = 1,240
191 (28.9)
48 (29.8)
97 (23.2)†
336 (27.1)
Alcohol use or abuse (ever), n = 1,240
257 (38.9)
61 (37.9)
148 (35.3)
466 (37.6)
Illicit drug use (ever)
131 (19.8)
38 (23.6)
77 (18.4)
246 (19.8)
Weight loss, n = 1,237
543 (82.5)
126 (78.8)
330 (78.8)
999 (80.8)
Dyspnea, n = 1,238
118 (17.9)
21 (13.1)
81 (19.3)
220 (17.8)
Hemoptysis, n = 1,239
28 (4.3)
9 (5.6)
38 (9.1)§
75 (6.1)
Cavitary lesion on chest radiography, n = 1,207
199 (16.5)
43 (3.6)
144 (11.9)
386 (32.0)
Low BMI, n = 1,233
203 (30.8)
55 (34.8)
133 (32.1)
391 (31.7)
Previous TB treatment
328 (49.6)
77 (47.8)
224 (53.5)
629 (50.7)
Type of TB
Pulmonary only
650 (98.3)
155 (96.3)
414 (98.8)
1219 (98.2)
Extrapulmonary
11 (1.7)
6 (3.7)
5 (1.2)
22 (1.8)
*Values are no. (%) except as indicated. Boldface indicates significant difference in statistical comparison of baseline characteristics in the corresponding
drug-resistance group to drug-susceptible cases. INH, isoniazid; RIF, rifampin; MDR TB, multidrug-resistant tuberculosis; DST, drug-susceptibility testing;
BMI, body mass index.
†p<0.05.
‡p<0.001.
§p<0.01.

failure, 4 (22.2%) were adults with a household contact,
and 1 (5.6%) had confirmed category I failure. BreslowDay tests for homogeneity indicated that the effect of adult
household contact on the odds of MDR TB is modified
by diabetes (p<0.0001), and that the effect of suspected
category I failure on the odds of MDR TB is modified
by diabetes (p = 0.0113). One patient with new smearpositive TB was suspected of failing category II treatment
(i.e., positive smear or culture during the second or third
month of category II therapy); this same patient met the
risk group criteria for adult household contact and private
or self-administered treatment. Among previously treated
patients with smear-positive TB, the following factors
were significantly associated with a higher relative risk for
MDR TB, compared with regional surveillance prevalence
estimates: adult household contact (51.4%), failure of
category I treatment (73.3%), early relapse after category
I treatment (40.0%), suspected (84.6%) or confirmed
(61.1%) failure of category II treatment, and history of >2
previous TB treatments (38.3%).

436

Discussion
We describe the proportion of drug resistance among
TB patients as detected by using the screening strategy
for MDR TB instituted in Lima, Peru, starting in 2005.
When these data were compared with nearly concurrent
population-based surveillance data, the proportion of MDR
TB among new and previously treated TB cases was found
to be significantly higher, indicating that screening highrisk patients may be an effective strategy. The proportion of
MDR TB detected among patients with new smear-positive
TB is comparable to that among previously treated patients
with smear-positive TB in the cohort (p = 0.458). In the
Peruvian NTP surveillance regional data corresponding to
the study area, the prevalence of MDR TB among patients
with new smear-positive TB was significantly lower than the
prevalence among previously treated patients with smearpositive TB (p<0.001). This finding shows that the strategy
implemented in Lima was especially effective in detecting
MDR TB among patients with new smear-positive TB.
The risk groups with the highest rates of MDR TB
were those with diabetes mellitus, adults or children with
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Table 3. Prevalence estimates of TB drug resistance from national and regional surveillance data, and proportion of drug resistance in
study cohort, Lima, Peru, 2005–2008*
Total no.
No. (%) susceptible No. (%) monoresistant
No. (%)
patients
to INH and RIF
to INH or RIF
MDR TB
Cohort
Peruvian NTP drug-resistance surveillance, national data (21)
All TB patients
2,167
1,829 (84.4)
158 (7.3)
180 (8.3)
New TB patients
1,816
1,597 (87.9)
124 (6.8)
95 (5.2)
Previously treated TB patients
351
232 (66.1)
34 (9.7)
85 (24.2)
Peruvian NTP drug-resistance surveillance, regional data corresponding to study area†
All TB patients
580
467 (80.5)
41 (7.1)
72 (12.4)
New TB patients
476
396 (83.2)
33 (6.9)
47 (9.9)
Previously treated TB patients
104
71 (68.3)
8 (7.7)
25 (24.0)
Study cohort
All TB patients
1,241
661 (53.3)
161 (13.0)
419 (33.8)
New TB patients
612
333 (54.4)
84 (13.7)
195 (31.9)
Previously treated TB patients
629
328 (52.2)
77 (12.2)
224 (35.6)
Study cohort, smear-positive samples only
All TB patients
1,114
581 (52.2)
143 (12.8)
390 (35.0)
New TB patients
531
278 (52.4)
73 (13.8)
180 (33.9)
Previously treated TB patients
583
303 (52.0)
70 (12.0)
210 (36.0)
*TB, tuberculosis; INH, isoniazid; RIF, rifampin; MDR, multidrug resistant; NTP, National Tuberculosis Control Program.
†Ministerio de Salud, Peru, unpub. data.

household contacts with known or suspected TB, suspected
failure of category I or II treatment (i.e., positive smear or
culture during the second or third month of therapy), failure
or early relapse to category I treatment, failure of category
II treatment, and multiple (>2) previous TB treatments.
Ample literature supports these findings in a variety of
settings (22–25). Screening for drug resistance among
these groups is easily implemented and should be strongly
considered by national TB programs.
In addition to identifying risk groups with high
prevalence of MDR TB, other considerations are pertinent
to the design of an optimal programmatic strategy. For

example, risk groups with a relatively low prevalence of
MDR TB may still merit DST if delays in initiation of MDR
TB treatment would have severe consequences (e.g., children
or HIV-positive patients) or if the absolute number of MDR
TB cases within that risk group is substantial (e.g., patients
with diabetes). The relative complexity of implementing
certain testing strategies is also a consideration. Compared
with alternative testing strategies such as universal testing or
testing by geographic region, a strategy that focuses on highrisk patients requires training health care workers to screen
each TB patient for numerous risk factors. Therefore, case
finding may be variable under routine program conditions.

Table 4. MDR TB among new smear-positive TB patients compared with regional surveillance prevalence estimates, by NTP risk
group, Lima, Peru, 2005–2008*
No. (%)
MDR TB
Risk factor
Total no. patients
Odds ratio (95% CI)
New smear-positive TB patients in NTP regional surveillance data
476
47 (9.9)
New smear-positive TB patients in study cohort
531
180 (33.9)
4.68 (3.30–6.65)
HIV positive
46
8 (17.4)
1.92 (0.85– 4.36)
Diabetes mellitus
107
18 (16.8)
1.85 (1.02–3.33)
NA
Chronic corticosteroid therapy
4
0
NA
Other immunosuppression
5
0
3.04 (0.06–38.63)
Adverse reaction
4
1 (25.0)
Previous hospitalization within the past 2 y with duration >15 d
5
2 (40.0)
6.09 (0.49–54.15)
1.83 (0.60–5.57)
Health care worker during the past 2 y
24
4 (16.7)
Health sciences student during the past 2 y
29
5 (17.2)
1.90 (0.69–5.22)
Prisoner during the past 2 y
27
4 (14.8)
1.59 (0.53–4.79)
4.60 (2.97–7.14)
Adult patient with household contact risk factor(s)†
170
57 (33.5)
Pediatric patient with household contact risk factor(s)†
13
7 (53.9)
10.65 (2.90–39.71)
NA
Private or self-administered treatment
2
2 (100.0)
18.26 (11.01–30.26)
Sputum positive during second or third month of category I treatment
105
70 (66.7)
Sputum positive during second or third month of category II treatment
1
1 (100.0)
NA
*MDR, multidrug resistant; TB, tuberculosis; NTP, National Tuberculosis Control Program; CI, confidence interval; NA, not applicable.
†Household contact risk factors are defined as household contact with a patient with known MDR TB, with a patient who showed TB treatment failure in
the past 2 y, or with a patient being treated with second-line TB drugs.
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Table 5. MDR TB among previously treated smear-positive TB patients compared with regional surveillance prevalence estimates, by
NTP risk group, Lima, Peru, 2005–2008*
Total no.
No. (%)
patients
MDR TB
Risk factor
Odds ratio (95% CI)
Previously treated smear-positive TB patients in NTP regional surveillance data
104
25 (24.0)
Previously treated smear-positive TB patients in study cohort
583
210 (36.0)
1.78 (1.10–2.88)
HIV positive
36
12 (33.3)
1.58 (0.69–3.61)
Diabetes mellitus
30
10 (33.3)
1.58 (0.65–3.82)
Adverse reaction
13
1 (7.7)
0.26 (0.01–1.97)
Previous hospitalization within the past 2 y with duration >15 d
4
1 (25.0)
1.05 (0.02–13.80)
Health care worker during the past 2 y
4
1 (25.0)
1.05 (0.02–13.80)
Health sciences student during the past 2 y
4
3 (75.0)
9.48 (0.71–503.7)
Prisoner during the past 2 y
24
4 (16.7)
0.63 (0.20–2.02)
Adult case with household contact risk factor(s)†
109
56 (51.4)
3.34 (1.86–6.00)
Pediatric case with household contact risk factor(s)†
7
3 (42.9)
2.37 (0.32–14.92)
Private or self-administered treatment
87
28 (32.2)
1.50 (0.79–2.83)
Sputum positive during second or third month of category I treatment
5
3 (60.0)
4.74 (0.50–58.69)
Sputum positive during second or third month of category II treatment
13
11 (84.6)
17.38 (3.36–166.8)
Failure of category I treatment‡
30
22 (73.3)
8.69 (3.44–21.93)
Relapsed within 6 mo after category I treatment§
65
26 (40.0)
2.11 (1.08–4.12)
Defaulted while receiving category I treatment¶
98
15 (15.3)
0.57 (0.28–1.16)
Failure of category II treatment‡
18
11 (61.1)
4.97 (1.74–14.18)
Relapsed within 6 mo after category II treatment§
8
5 (62.5)
5.27 (0.93–35.66)
Defaulted while receiving category II treatment¶
63
16 (25.4)
1.08 (0.52–2.22)
253
97 (38.3)
1.96 (1.17–3.29)
Chronic treatment (>2 prior treatments)#
*MDR, multidrug resistant; TB, tuberculosis; CI, confidence interval; NTP, National Tuberculosis Control Program.
†Household contact risk factors are defined as household contact with a patient with known MDR TB, with a patient who showed TB treatment failure in
the past 2 y, or with a patient being treated with second-line TB drugs.
‡Defined as positive smear and/or culture after >4 mo of treatment, or positive smear and/or culture upon finishing treatment.
§Defined as recurrence of disease <6 mo after being classified as cured by NTP norms.
¶Defined as not receiving treatment >1 mo upon enrollment into the study.
#Defined as a history of >2 previous TB treatments.

The findings of this evaluation are subject to several
limitations. Although our study personnel would visit local
health establishments in a purely observational capacity, the
frequent visits by data collectors in the health centers could
have sensitized health care workers to follow screening
and referral protocols more closely than they would have
otherwise. In addition, given the use of phenotypic methods,
the drug-resistance status of particular isolates could be
determined only for culture-positive samples. Although
the yield of positive cultures was high for all methods used
(67.4% for indirect conventional DST, 78.5% for direct
NRA, and 35.3% for largely paucibacillary or smearnegative samples submitted for BACTEC; data not shown),
the contribution to relative risk of MDR TB among those
without DST results could not be determined. These results
call attention to one of the shortcomings of all phenotypic
methods, i.e., a substantial fraction of patients never have
positive cultures or DST results to confirm the diagnosis
or guide therapy, despite being at high risk for having
MDR TB. Nonetheless, the yield of positive cultures in
our sample is similar to that obtained by programs that
have used the same sputum-processing methods (N-acetylL-cysteine and centrifugation, with cultivation on LJ
medium). Finally, this evaluation was observational in
nature and lacks a concurrent comparison group, such as
438

one that had undergone an alternative screening strategy.
On the other hand, this study has key strengths. The
programmatic nature of this intervention, an active field
presence to capture accurate and complete data on a large
cohort, and the fortuitous concurrent surveillance study
have allowed us to assess the effects of these programmatic
efforts to identify patients with MDR TB.
To date, little research has been conducted on the
comparative effectiveness of varied approaches to MDR
TB screening and treatment referral. To our knowledge,
the only study to show clinical results for performing rapid
DST is a retrospective study carried out in California,
which showed that using a molecular beacon assay led to
earlier diagnosis and treatment initiation for MDR TB (26).
An important aspect of program evaluation is feedback
of findings to further improve treatment programs. In
Peru, the results of this evaluation have been conveyed to
the NTP and NRL. The aim of this communication is to
describe an intensive evaluation of one of Peru’s public
health strategies for improving MDR TB control. In
other low- to middle-income countries, similar program
evaluations should be implemented to clarify national and
regional MDR TB epidemiology, identify key risk groups
for MDR TB, and inform national strategies to diagnose
and treat MDR TB. Ultimately, the effects of these changes
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on turn-around time, time to culture conversion, cure rates,
and costs will determine the comparative success of these
strategies.
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